Written by A. Nair, a PharmTech correspondent based in Mumbai
After months of deliberation, the Indian government has decided not to cap foreign direct investment (FDI) in the pharmaceutical sector and to continue with the 100% FDI regime. A decision in this regard was taken by an inter ministerial group presided over by India’s Prime Minister Manmohan Singh, which sought to allay fears about clearing investments automatically. Read more »
Multinational drug firms have been circling India, waiting for the opportune moment to enter the market. With several domestic pharmaceutical giants ripe for the picking, it is only a matter of time before they may be acquired by global firms. Thus far, price is the primary obstacle holding back suitors such as Teva, Merck KGa, Boerhinger Ingelheim, Pfizer, and GlaxoSmithKline.
It was her first port of call and it was steeped in symbolism.
At 7:30 am in Mumbai on July 18, Hillary Rodham Clinton’s private, cosy tete-a-tete with 10 of India Inc’s most sought-after billionaires, was a power breakfast the likes of which the city’s corporate czars had not seen in a long time. The meeting was anything but cozy, with participants hungry to take in every morsel. Read more »
There is a phrase in India that has become not so much a commonplace as a vulgar truism, one that people reach for quickly to describe India’s financial capital’s indomitable nature: the spirit of Mumbai. The terror attacks of November, that ripped asunder the very fabric of this resolute city, has dented that spirit. Somewhat. Read more »
From PharmTech.com